Free Trial

10 Best Penny Stocks to Buy Now - 7 of 10

 
 

Assertio (NASDAQ:ASRT)

Number of Upgrades from Top-Ranked Analysts
3 (in the last 90 days)
Consensus Rating
Buy
Rating Score
3.0
Ratings Breakdown
3 Buy Ratings, 0 Hold Ratings, 0 Sell Ratings.
Consensus Price Target
$3.25 (282.4% Upside)

About Assertio

Assertio logoAssertio Holdings, Inc, a commercial pharmaceutical company, provides various products to patients in the United States. Its pharmaceutical products include INDOCIN, an oral and suppository solution for the treatment of moderate to severe rheumatoid arthritis, including acute flares of chronic disease; ankylosing spondylitis and osteoarthritis; and acute painful shoulder and gouty arthritis. Read More 
 

Recent Analyst Ratings

DateBrokerageActionRatingPrice TargetDetails
7/26/2024Maxim GroupInitiated CoverageBuy$3.00
7/3/2024HC WainwrightInitiated CoverageBuy$4.00
5/28/2024Alliance Global PartnersInitiated CoverageBuy$2.75
11/3/2023BWS FinancialLower Price TargetBuy ➝ Buy$6.00 ➝ $4.00
8/4/2023BWS FinancialLower Price TargetBuy ➝ Buy$10.00 ➝ $6.00
8/4/2023Lake Street CapitalLower Price Target$9.00 ➝ $7.00
5/10/2023BWS FinancialBoost Price Target$8.00 ➝ $10.00
5/10/2023Lake Street CapitalBoost Price Target$8.00 ➝ $9.00
3/3/2023BWS FinancialBoost Price TargetBuy$6.00 ➝ $8.00
11/7/2022Lake Street CapitalInitiated CoverageBuy$7.00
 

Elon knows the truth, which is why they want him silenced (Ad)

Elon Musk is one of mankind’s greatest innovators. But for all his visionary prowess and contributions to humanity, there is a war being waged on Elon Musk. This war has nothing to do with X, Elon’s stance on immigration.

Watch this new documentary and you’ll discover what Elon knows,